EP3473101B1 - Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires pour les félins - Google Patents

Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires pour les félins Download PDF

Info

Publication number
EP3473101B1
EP3473101B1 EP18205103.7A EP18205103A EP3473101B1 EP 3473101 B1 EP3473101 B1 EP 3473101B1 EP 18205103 A EP18205103 A EP 18205103A EP 3473101 B1 EP3473101 B1 EP 3473101B1
Authority
EP
European Patent Office
Prior art keywords
isoxazoline
compound
day
efficacy
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18205103.7A
Other languages
German (de)
English (en)
Other versions
EP3473101A1 (fr
Inventor
Anja Regina HECKEROTH
Jürgen Lutz
Christina Mertens
Heike Williams
Hartmut Zoller
Takeshi Mita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40152741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3473101(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of EP3473101A1 publication Critical patent/EP3473101A1/fr
Application granted granted Critical
Publication of EP3473101B1 publication Critical patent/EP3473101B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/10—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof
    • A01N47/12—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof containing a —O—CO—N< group, or a thio analogue thereof, neither directly attached to a ring nor the nitrogen atom being a member of a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/10—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof
    • A01N47/18—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof containing a —O—CO—N< group, or a thio analogue thereof, directly attached to a heterocyclic or cycloaliphatic ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N53/00—Biocides, pest repellants or attractants, or plant growth regulators containing cyclopropane carboxylic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to compositions comprising the isoxazoline of formula 11-1 for use in the control of parasite infestations of an animal.
  • a number of pests and parasites are known to infest warm-blooded animals. These pests and parasites can be great nuisances to both the animals and their owners. For example, virtually all companion and livestock animals can be affected by ectoparasites, such as ticks, mites, lice, and fleas. Ectoparasites tend to irritate the animals, and also can cause clinical disease and adverse sub-clinical conditions, either by themselves or by carrying vector-transmitted pathogens. To date, various treatments have been developed to control ectoparasites on warm-blooded animals.
  • compositions that are bioavailable, can provide contact or systemic activity, are potently efficacious, have a quick onset of activity, have a long duration of activity, and/or are safe to the animal recipients and/or their human owners.
  • This invention addresses this need.
  • the invention is directed to an isoxazoline of Formula (11-1) for use in the control of parasite infestations of an animal, wherein an amount of 0.01 to 200 mg/ kg bodyweight of the isoxazoline or a salt of the isoxazoline, or a solvate of the isoxazoline or salt, that is effective to control an ectoparasitic infestation is administered in combination with one or more macrocyclic lactone endectocidal parasiticides selected from ivermectin, abamectin, doramectin, moxidectin, selamectin, milbemycin, emamectin and eprinomectin , at a bi-monthly, quarterly, half-yearly, or longer frequency and wherein the weight ratio of the isoxazoline compound and the macrocyclic lactone endectocidal parasiticides is from 1:3000 to 3000:1 .
  • compositions generally show desirable bioavailability, and can provide contact and/or systemic activity. Many of the compositions also provide desirable safety profiles toward the warm-blooded animal recipients and/or their owners. In addition, it has been discovered that a single administration of such compositions generally provides potent activity against one or more ectoparasites, while also tending to provide fast onset of activity, long duration of activity, and/or desirable safety profiles.
  • Figure 1 shows the mean plasma concentration of Compound 11-1 during the study in Example 6, which assesses the efficacy of Compound 11-1 against cat fleas ( Ctenocephalides felis ) and brown dog ticks ( Rhipicephalus sanguineus ) in dogs.
  • the "PO" data refers to Group A (1 mg/kg body weight Compound 11-1 in the form of a tablet for oral administration);
  • the "SC” data refers to Group B (1 mg/kg body weight Compound 11-1 in the form of an injectable solution for subcutaneous administration);
  • the "TOP W/ ENH” data refers to Group C (1 mg/kg body weight Compound 11-1 in the form of a topical spot-on solution containing an absorption enhancer);
  • the "TOP W/ ENH & SPREAD” data refers to Group D (1 mg/kg body weight Compound 11-1 in the form of a topical spot-on solution containing an absorption enhancer and spreading agent);
  • the "TOP W/ ETHYL LACTATE” data refers to Group E (1 mg/kg body weight Compound 11-1 in the form of a topical spot-on solution containing ethyl lactate as a solvent).
  • the isoxazoline used in accordance with this invention has Formula 11-1.
  • Examples of comparative isoxazolines include the following:
  • the isoxazoline used in the present invention has the following formula:
  • Comparative isoxazolines include the following:
  • the isoxazoline used in this invention generally can have two or more conformational structures.
  • the isoxazoline comprises a chiral (or asymmetric) carbon at the 5-position of the isoxazoline ring.
  • the chiral carbon has a left-handed (or "S" or "sinister”) configuration.
  • S left-handed
  • the chiral carbon has a right-handed (or "R” or "rectus”) configuration.
  • the isoxazoline may additionally have other conformational isomers, such as, for example, substituents with a cis or trans double bond.
  • a specific isomer often can be isolated from the corresponding racemic mixture (or a salt thereof) using, for example, chiral high performance liquid chromatography (HPLC) techniques. Such a technique is illustrated in Example 7 below for isolating the R and S enantiomers of racemic Compound 11-1.
  • HPLC high performance liquid chromatography
  • a more-easily-isolatable derivative of the isomer is isolated from the corresponding derivative racemic mixture (or a salt thereof), and then converted to the isomer.
  • a specific isomer often can be directly synthesized from, for example, an optically pure starting material.
  • the ratio of one enantiomer (e.g., Compound 17-1) to another enantiomer (e.g ., Compound 11-1R) in the pharmaceutical composition used with this invention is greater than 1:1. In some instances, for example, the ratio is greater than about 70:30, greater than about 85:15, greater than about 90:10, greater than about 95:5, greater than about 98:2, or greater than about 99:1.
  • the concentration of one enantiomer (e.g ., Compound 17-1) in the composition (or, more typically, a precursor composition) is greater than about 50% (by weight). In some such embodiments, for example, the concentration is greater than about 70% (by weight), greater than about 85% (by weight), greater than about 90% (by weight), greater than about 95% (by weight), greater than about 98% (by weight), greater than about 99% (by weight), or greater than about 99.5% (by weight).
  • a isoxazoline structure that does not indicate a particular conformation is intended to encompass compositions of all the possible conformational isomers of the isoxazoline, as well as compositions comprising fewer than all (e.g., just one of) the possible conformational isomers.
  • theisoxazoline used with this invention may be in the form of a salt.
  • a salt may be advantageous due to one or more of its physical properties, such as pharmaceutical stability in differing temperatures and humidities; crystalline properties; and/or a desirable solubility in water, oil, or other solvents.
  • Acid and base salts typically can be formed by, for example, mixing a compound with an acid or base, respectively, using various known methods in the art.
  • the salt when the salt is intended to be administered in vivo ( i.e., to an animal) for a therapeutic benefit, the salt preferably is pharmaceutically acceptable.
  • a base addition salt of the isoxazoline of Formula (11-1) can be prepared by reacting the isoxazoline with an approximately stoichiometric amount of an inorganic or organic base, typically a strong inorganic or organic base.
  • base addition salts may include, for example, metallic salts, and organic salts.
  • Metallic salts include alkali metal (group la, e.g., lithium, sodium, or potassium) salts, alkaline earth metal (group IIa, e.g ., barium, calcium, and magnesium) salts, heavy metal (e.g., zinc and iron) salts, and other physiologically acceptable metal salts.
  • Such salts may be made from calcium, lithium, magnesium, potassium, sodium, and zinc.
  • a free acid isoxazoline may be mixed with sodium hydroxide to form such a base addition salt.
  • an acid addition salt of the isoxazoline of Formula (11-1) can be prepared by reacting the isoxazoline with an approximately stoichiometric amount of an inorganic or organic acid.
  • contemplated inorganic acids for making pharmaceutically acceptable salts include hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid.
  • organic acids for making pharmaceutically acceptable salts generally include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.
  • organic acids include cholic, sorbic, lauric, acetic, trifluoroacetic, formic, propionic, succinic, glycolic, gluconic, digluconic, lactic, malic, tartaric acid, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, aryl carboxylic acid (e.g ., benzoic), anthranilic acid, mesylic, stearic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), alkylsulfonic (e.g., ethanesulfonic), arylsulfonic (e.g., benzenesulfonic), pantothenic, 2-hydroxyethanesulfonic, sulfanilic, cyclohexylaminosulfonic, ⁇ -hydroxybutyric, galactaric, galactu
  • an organic salt of the isoxazoline of Formula (11-1) may be made by, for example, quaternizing a basic nitrogen-containing group on the isoxazoline with an agent such as a C 1 -C 6 -alkyl halide (e.g ., methyl, ethyl, propyl, and butyl chlorides, bromides, or iodide), dialkyl sulfate ( e.g ., dimethyl, diethyl, dibuytl, or diamyl sulfate), long chain halide ( e.g., decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodide), arylalkyl halide (e.g ., benzyl and phenethyl bromide), and the like.
  • a C 1 -C 6 -alkyl halide e.g methyl, ethyl, prop
  • an acid or base salt may, in some instances, be optically active (e.g ., D-lactate and L-lysine salts) or racemic (e.g ., DL-tartrate and DL-arginine salts).
  • optically active e.g ., D-lactate and L-lysine salts
  • racemic e.g ., DL-tartrate and DL-arginine salts
  • the isoxazoline of Formula (11-1) is in the form of stable complexes with solvent molecules that remain intact after the non-complexed solvent molecules are removed from the compounds. These complexes generally are referred to as "solvates.” In some instances, the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid.
  • a “solvate” encompasses both solution-phase and isolatable solvates. Examples of suitable solvates include ethanolates, methanolates, and the like.
  • a "hydrate” is a solvate wherein the solvent molecule is water.
  • a solvate intended to be used in vivo preferably is pharmaceutically acceptable.
  • the isoxazoline of Formula (11-1) generally may be used to control ectoparasites on animals, and, in turn, diseases directly caused by such ectoparasites and/or diseases caused by pathogens carried by such ectoparasites. It is contemplated that the composition may be used to treat a range of animals, especially warm-blooded animals. Such warm-blooded animals include, for example, mammals. Mammals include, for example, humans.
  • Other mammals include, for example, farm or livestock mammals (e.g., swine, bovines, sheep, goats, etc.), laboratory mammals (e.g., mice, rats, jirds, etc.), companion mammals (e.g., dogs, cats, equines, etc.), fur-bearing animals (e.g., minks, foxes, chinchillas, rabbits, etc.), and wild and zoo mammals (e.g ., buffalo, deer, etc.).
  • farm or livestock mammals e.g., swine, bovines, sheep, goats, etc.
  • laboratory mammals e.g., mice, rats, jirds, etc.
  • companion mammals e.g., dogs, cats, equines, etc.
  • fur-bearing animals e.g., minks, foxes, chinchillas, rabbits, etc.
  • wild and zoo mammals e.g
  • the compositions are used to treat canines (e.g ., dogs, such as, for example, pure-bred and/or mongrel companion dogs, show dogs, working dogs, herding dogs, hunting dogs, guard dogs, police dogs, racing dogs, and/or laboratory dogs).
  • the compositions are used to treat felines (e.g. , domestic cats). It is contemplated that the compositions also are suitable to treat non-mammals, such as birds ( e.g ., turkeys, chickens, geese, ducks, parrots, etc.). It is also contemplated that such compositions may be useful to treat cold-blooded animals as well, such as, for example, fish ( e.g ., salmon, trout, koi, etc.).
  • the isoxazoline of Formula (11-1) is generally of particular value for controlling ectoparasites, i.e., arthropods that are injurious to, or spread or act as vectors of diseases in, warm-blooded animals.
  • the isoxazolines are generally beneficial for controlling various lifecycle stages of parasites, including egg, nymph, larvae, juvenile, and adult stages.
  • Ectoparasites generally insect and acarid pests
  • infestation refers to the presence of parasites in numbers that pose a risk of nuisance or harm to humans or animals.
  • the presence can be in the environment (e.g., in animal bedding), on the skin or fur of an animal, etc.
  • infestation is intended to be synonymous with the term, "infection,” as that term is generally understood in the art.
  • control of ectoparasite infestation means to reduce or eradicate parasite numbers in and/or on an animal, and/or to partially or completely inhibit the development of parasite infestation in and/or on an animal. This may be achieved by, for example, killing, repelling, expelling, incapacitating, deterring, eliminating, alleviating, or minimizing the parasite.
  • the control of ectoparasites can be insecticidal and/or acaricidal.
  • the effect of the isoxazoline can be, for example, ovicidal, larvicidal, nymphicidal, adulticidal, or a combination thereof.
  • the effect can manifest itself directly by killing the parasites either immediately or after some time has elapsed (e.g., when molting occurs or by destroying eggs).
  • the effect alternatively (or additionally) can manifest itself indirectly by, for example, reducing the number of eggs laid and/or the hatch rate.
  • an amount of a isoxazoline that is sufficient to "control" or be “effective” against a target parasite is an amount that is sufficient to reduce or eradicate parasite numbers in and/or on an animal, and/or to partially or completely inhibit the development of parasite infestation in and/or on an animal.
  • an effective amount generally constitutes an amount that results in tissue and/or blood concentrations generally toxic when ingested by a target parasite.
  • a dose is considered effective for controlling a target parasite when the dose is sufficient to cause an existing or potential target parasite count to be reduced by at least about 5%.
  • the dose is considered effective when the dose is sufficient to cause an existing or potential parasite count to be reduced by at least about 10% (or at least about 30%, at least about 50%, at least about 60%, at least about 75%, at least about 90%, at least about 95%, or at least about 99%).
  • the optimum dosage generally depends on multiple factors, including, for example, the particular isoxazoline; the identity of any other active ingredient(s) being administered to the animal recipient; the route of administration; the type and severity of the target condition and pathogen; the type (e.g., species and breed), age, size, sex, diet, activity, and condition of the intended animal recipient; and pharmacological considerations, such as the activity, efficacy, pharmacokinetic, and toxicology profiles of the isoxazoline and other active ingredient(s) being administered to the recipient animal.
  • the amount of each ingredient that constitutes an "effective amount" is an amount that, when combined with the other active ingredients, causes the desired effect.
  • the isoxazoline of Formula (11-1) may be administered multiple times for a single treatment.
  • a single dose is administered to effectively control a target parasite for a longer duration.
  • the single dose is effective to control a target parasite for at least about 2 weeks, at least about 3 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, or at least about 6 months.
  • the frequency of treatments is bi-monthly, quarterly, half yearly, or even longer ( e.g ., yearly).
  • the durations over which the isoxazoline of Formula (11-1) tend to be effective against various ectoparasites by systemic administration is surprising.
  • the isoxazoline dose and formulation are chosen to maintain a isoxazoline serum level of at least about 1 ng/ml (e.g., 1 to 50 ng/ml).
  • the amount of isoxazoline administered to the animal recipient is from about 0.001 to about 200 mg/kg body weight. In some embodiments, for example, from about 0.01 to about 200 mg/kg body weight is administered. In other embodiments, for example, from about 0.001 to about 100 mg/kg body weight is administered. In some such embodiments, for example, from about 0.01 to about 100 mg/kg body weight is administered. In other such embodiments, from about 1 to about 30 mg/kg body weight is administered. Greater dosages tend to provide for greater duration of activity.
  • the duration of activity of the isoxazoline can be extended even further (or made more consistent) by using a controlled-release formulation or dosage form.
  • the isoxazoline can be administered in microspheres, granules, or implants ( e.g ., a subcutaneous implant) that release the isoxazoline by, example, diffusion and/or erosion.
  • Use of such a dosage form containing from about 1 and about 50 mg/kg body weight (or from about 10 to about 30 mg/kg body weight, such as about 20 mg/kg of body weight) of the isoxazoline may allow for consistent activity lasting over several months or longer ( e.g., a year).
  • the isoxazoline of Formula (11-1) is administered to treat parasitoses of an animal (or make a medicament to treat parasitoses of an animal).
  • parasitoses includes pathologic conditions and diseases associated with or caused by one or more ectoparasites directly, such as, for example, anemia and flea allergy dermatitis. It also includes pathologic conditions or diseases associated with caused by one or more vector-transmitted pathogens, such as, for example, Lyme disease, ehrlichiosis (particularly canine ehrlichiosis), and Rocky Mountain spotted fever from vector ticks.
  • treatment of parasitoses means to partially or completely inhibit the development of parasitoses of an animal susceptible to parasitoses, reduce or completely eliminate the symptoms of parasitoses of an animal having parasitoses, and/or partially or completely cure parasitoses of an animal having parasitoses.
  • the treatment of parasitoses is achieved by administering the isoxazoline of Formula (11-1) to control an ectoparasite infestation.
  • This invention also relates to treatment methods wherein at least an ancillary goal of controlling ectoparasites in and/or on an animal is to control an ectoparasitic infestation in an environment that is occupied (periodically or continuously) by the animal.
  • the animal is a companion animal (e.g., a cat or dog).
  • the environment may be, for example, a house or other shelter; a room; a pen, a stall, or other confinement means; bedding; etc.
  • systemic administration refers to the delivery of the isoxazoline of Formula (11-1), salt of the isoxazoline, solvate of the isoxazoline or salt, or prodrug of the isoxazoline.
  • systemic administration is desirable.
  • Systemic administration is an administration at a site remote from a site wherein at least a portion of the target parasites reside. With systemic administration, at least a portion of the isoxazoline reaches the target parasite via the animal recipient's bloodstream, other body fluids (lymph fluids), and/or tissues (e.g ., skin or fat tissue). Typically, the parasite ingests the isoxazoline along with the animal recipient's blood, other body fluids, and/or tissue.
  • Systemic administration may be achieved in several forms.
  • the isoxazoline composition is systemically administered via an oral route in a unit dosage form, such as, for example, a soft or hard capsule, a pill, a powder, granules, a tablet (e.g., a chewable tablet), a paste, a solution, a suspension (aqueous or non-aqueous), an emulsion (oil-in-water or water-in-oil), an elixir, a syrup, a bolus, a drench, or via the animal recipient's feed or drinking water.
  • a unit dosage form such as, for example, a soft or hard capsule, a pill, a powder, granules, a tablet (e.g., a chewable tablet), a paste, a solution, a suspension (aqueous or non-aqueous), an emulsion (oil-in-water or water-in-oil), an elixir, a syrup, a bolus, a d
  • the composition may, for example, be intimately dispersed in the animal recipient's regular feed, used as a top dressing, or in the form of pellets or liquid that is added to the finished feed.
  • a feed additive it may be convenient to prepare a "premix” in which the composition is dispersed in a liquid or solid carrier. This "premix” is, in turn, dispersed in the animal's feed using, for example, a conventional mixer.
  • a solution or suspension formulation can be, for example, a concentrated suspension that is mixed with water or a dry preparation that is mixed and suspended in the water. In both instances, it is preferable to have the isoxazoline in a finely-pulverized form.
  • the isoxazoline composition alternatively (or additionally) may be systemically administered topically using a transdermal formulation (i.e., a formulation that passes through the skin). Alternatively (or additionally), the composition may be systemically administered topically via the mucosa.
  • Typical formulations for transdermal and mucosal administration include, for example, pour-ons, spot-ons, dips, sprays, mousses, shampoos, powders, gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, limb bands, collars, ear tags, wafers, sponges, fibers, bandages, and microemulsions.
  • the pour-on or spot-on methods comprise applying the isoxazoline composition to a specific location of the skin or coat, such as on the neck or backbone of the animal. This may be achieved by, for example, applying a swab or drop of the pour-on or spot-on formulation to a relatively small area of the recipient animal's skin or coat ( i.e., generally no greater than about 10% of the animal recipient's skin or coat).
  • the isoxazoline is dispersed from the application site to wide areas of the fur due to the spreading nature of the components in the formulation and the animal's movements while, in parallel, being absorbed through the skin and distributed via the animal recipient's fluids and/or tissues.
  • the isoxazoline composition alternatively (or additionally) may be systemically administered parenterally, such as via intramuscular injection, intravenous injection, subcutaneous injection, implant ( e.g ., subcutaneous implant), infusion, bolus, etc.
  • parenteral dosage form provides the animal recipient with from about 0.01 to about 200 mg/kg body weight of the isoxazoline.
  • contemplated modes of administration include, for example, rectal, vaginal, and via inhalation (e.g., via a mist or aerosol).
  • compositions comprising the isoxazoline of Formula (11-1), salt of the isoxazoline, solvate of the isoxazoline or salt.
  • compositions also may (and generally will) comprise one or more pharmaceutically-acceptable excipients.
  • compositions of the present invention may be manufactured by, for example, processes known in the art. These processes include, for example, a variety of known mixing, dissolving, granulating, emulsifying, encapsulating, entrapping, and lyophilizing processes. Optimal formulation depends on, for example, the route of administration.
  • Solid dosage forms may be prepared by, for example, intimately and uniformly mixing the isoxazoline with fillers, binders, lubricants, glidants, disintegrants, flavoring agents (e.g ., sweeteners), buffers, preservatives, pharmaceutical-grade dyes or pigments, and controlled release agents.
  • fillers binders, lubricants, glidants, disintegrants, flavoring agents (e.g ., sweeteners), buffers, preservatives, pharmaceutical-grade dyes or pigments, and controlled release agents.
  • Oral dosage forms other than solids may be prepared by mixing the isoxazoline with, for example, one or more solvents, viscosity-enhancing agents, surfactants, preservatives, stabilizers, resins, fillers, binders, lubricants, glidants, disintegrants, co-solvents, sweeteners, flavorings, perfuming agents, buffers, suspending agents, and pharmaceutical-grade dyes or pigments.
  • solvents for example, one or more solvents, viscosity-enhancing agents, surfactants, preservatives, stabilizers, resins, fillers, binders, lubricants, glidants, disintegrants, co-solvents, sweeteners, flavorings, perfuming agents, buffers, suspending agents, and pharmaceutical-grade dyes or pigments.
  • Contemplated binders include, for example, gelatin, acacia, and carboxymethyl cellulose.
  • Contemplated lubricants include, for example, magnesium stearate, stearic acid, and talc.
  • Contemplated disintegrants include, for example, corn starch, alginic acid, sodium carboxymethylcellulose, and sodium croscarmellose.
  • Contemplated buffers include, for example, sodium citrate, and magnesium and calcium carbonate and bicarbonate.
  • Contemplated solvents include, for example, water, petroleum, animal oils, vegetable oils, mineral oil, and synthetic oil.
  • Physiological saline solution or glycols e.g., ethylene glycol, propylene glycol, or polyethylene glycol
  • the solvent preferably has sufficient chemical properties and quantity to keep the isoxazoline solubilized at temperatures in which the composition is stored and used.
  • Contemplated viscosity-enhancing agents include, for example, polyethylene, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium alginate, carbomer, povidone, acacia, guar gum, xanthan gum, tragacanth, methylcellulose, carbomer, xanthan gum, guar gum, povidone, sodium carboxymethylcellulose, magnesium aluminum silicate, carboxyvinyl polymers, carrageenan, hydroxyethyl cellulose, laponite, water-soluble salts of cellulose ethers, natural gums, colloidal magnesium aluminum silicateor finely divided silica, homopolymers of acrylic acid crosslinked with an alkyl ether of pentaerythritol or an alkyl ether of sucrose, and carbomers.
  • Contemplated surfactants include, for example, polyoxyethylene sorbitan fatty acid esters; polyoxyethylene monoalkyl ethers; sucrose monoesters; lanolin esters and ethers; alkyl sulfate salts; and sodium, potassium, and ammonium salts of fatty acids.
  • Contemplated preservatives include, for example, phenol, alkyl esters of parahydroxybenzoic acid (e.g ., methyl p -hydroxybenzoate (or “methylparaben”) and propyl p-hydroxybenzoate (or “propylparaben”)), sorbic acid, o-phenylphenol benzoic acid and the salts thereof, chlorobutanol, benzyl alcohol, thimerosal, phenylmercuric acetate and nitrate, nitromersol, benzalkonium chloride, and cetylpyridinium chloride.
  • parahydroxybenzoic acid e.g methyl p -hydroxybenzoate (or “methylparaben”) and propyl p-hydroxybenzoate (or “propylparaben”
  • sorbic acid e.g methyl p -hydroxybenzoate (or "methylparaben”) and propyl p-hydroxybenzoate (or “propylparaben
  • Contemplated stabilizers include, for example, chelating agents and antioxidants.
  • Solid dosage forms also may comprise, for example, one or more excipients to control the release of the isoxazoline.
  • the isoxazoline may be dispersed in, for example, hydroxypropylmethyl cellulose.
  • Some oral dosage forms e.g., tablets and pills
  • enteric coatings e.g., enteric coatings.
  • Topical administration may be achieved using, for example, a concentrated solution, suspension (aqueous or non-aqueous), emulsion (water-in-oil or oil-in-water), or microemulsion comprising a isoxazoline dissolved, suspended, or emulgated in a pharmaceutically-acceptable liquid vehicle.
  • a crystallization inhibitor optionally may generally be present.
  • a liquid formulation When a liquid formulation is used topically on skin, it can be administered by, for example, pouring on, spreading, rubbing, atomizing, spraying, dipping, bathing, or washing.
  • a pour-on or spot-on formulation for example, can be poured or atomized onto a limited spot on the skin (typically no greater than about 10% of the skin).
  • the formulation allows or facilitates the isoxazoline to penetrate the skin and act on other parts body (e.g., the entire body).
  • Such a pour-on or spot-on formulation can be prepared by dissolving, suspending, or emulsifying the isoxazoline in a suitable skin-fitted solvent or solvent mixture.
  • Contemplated solvents include, for example, water, alkanol, glycol, polyethylene glycol, polypropylene glycol, glycerin, benzyl alcohol, phenylethanol, phenoxyethanol, ethyl acetate, butyl acetate, benzyl benzoate, dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, acetone, methyl ethyl ketone, aromatic and/or aliphatic hydrocarbons, vegetable or synthetic oil, DMF, liquid paraffin, silicone, dimethylacetamide, N-methylpyrrolidone, or 2,2-dimethyl-4-oxy-methylene-1,3-dioxolane.
  • Contemplated solvents include, for example, water, alkanol, glycol, polyethylene glycol, polypropylene glycol, glycerin, benzyl alcohol, phenylethanol, phenoxyethanol, ethyl acetate, butyl acetate,
  • a topical formulation (particularly a pour-on or spot-on formulation) comprises a carrier that promotes the absorption or penetration of the isoxazoline through the skin into the blood stream, other bodily fluids (lymph), and/or body tissue (fat tissue).
  • Contemplated examples of dermal penetration enhancers include, for example, dimethylsulfoxide, isopropyl myristate, dipropylene glycol pelargonate, silicone oil, aliphatic esters, triglycerides, and fatty alcohols.
  • Topical formulations also (or alternatively) may comprise, for example, one or more spreading agents.
  • These substances act as carriers that assist in distributing an active ingredient over the animal recipient's coat or skin. They may include, for example, isopropyl myristate, dipropylene glycol pelargonate, silicone oils, fatty acid esters, triglycerides, and/or fatty alcohols.
  • Various spreading oil/solvent combinations also may be suitable, such as, for example, oily solutions, alcoholic and isopropanolic solutions (e.g., solutions of 2-octyl dodecanol or oleyl alcohol), solutions of esters of monocarboxylic acids (e.g ., isopropyl myristate, isopropyl palmitate, lauric acid oxalic ester, oleic acid oleyl ester, oleic acid decyl ester, hexyl laurate, oleyl oleate, decyl oleate, and caproic acid esters of saturated fatty alcohols having a carbon chain of 12 to 18 carbons), solutions of esters of dicarboxylic acids (e.g ., dibutyl phthalate, diisopropyl isophthalate, adipic acid diisopropyl ester, and di-n-butyl adipate), or solutions of esters of est
  • the formulation comprises a spreading agent
  • a dispersant such as, for example, pyrrolidin-2-one, N-alkylpyrrolidin-2-one, acetone, polyethylene glycol or an ether or ester thereof, propylene glycol, or synthetic triglycerides.
  • the isoxazoline may be mixed with, for example, either a paraffinic or a water-miscible ointment base.
  • the isoxazoline may be formulated with, for example, an oil-in-water cream base.
  • the aqueous phase of the cream base includes, for example at least about 30% (w/w) of a polyhydric alcohol, such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol, or a mixture thereof.
  • Injectable preparations may be formulated according to, for example, the known art using suitable solvents, solubilizing agents, protecting agents, dispersing agents, wetting agents, and/or suspending agents.
  • Contemplated carrier materials include, for example, water, ethanol, butanol, benzyl alcohol, glycerin, 1,3-butanediol, Ringer's solution, isotonic sodium chloride solution, bland fixed oils ( e.g ., synthetic mono- or diglycerides), vegetable oil ( e.g., corn oil), dextrose, mannitol, fatty acids ( e.g., oleic acid), dimethyl acetamide, surfactants ( e.g ., ionic and non-ionic detergents), N-methylpyrrolidone, propylene glycol, and/or polyethylene glycols (e.g., PEG 400).
  • Contemplated solubilizing agents include, for example, polyvinyl pyrrolidone, polyoxyethylated castor oil, polyoxyethylated sorbitan ester, and the like.
  • Contemplated protecting agents include, for example, benzyl alcohol, trichlorobutanol, p-hydroxybenzoic acid ester, n -butanol, and the like.
  • a parenteral formulation is, for example, prepared from sterile powders or granules having one or more of the carriers materials discussed above for other formulations.
  • the isoxazoline is, for example, dissolved or suspended in a liquid comprising water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers.
  • the pH generally may be adjusted, if necessary, with a suitable acid, base, or buffer.
  • a suppository may be used for rectal administration.
  • the suppository may be prepared by, for example, mixing a isoxazoline with a suitable non-irritating excipient that is solid at ordinary temperatures, but liquid at the rectal temperature, and will, therefore, melt in the rectum to release the drug.
  • Contemplated excipients include, for example, such as cocoa butter; synthetic mono-, di-, or triglycerides; fatty acids; and/or polyethylene glycols.
  • inert ingredients may generally be added to the composition as desired.
  • these may include, for example, lactose, mannitol, sorbitol, calcium carbonate, sodium carbonate, tribasic calcium phosphate, dibasic calcium phosphate, sodium phosphate, kaolin, compressible sugar, starch, calcium sulfate, dextro or microcrystalline cellulose, colloidal silicon dioxide, starch, sodium starch glycolate, crospovidone, microcrystalline cellulose, tragacanth, hydroxypropylcellulose, pregelatinized starch, povidone, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and methylcellulose.
  • the concentration of the isoxazoline of Formula (11-1) (or any salt of the isoxazoline, solvate of the isoxazoline or salt, or prodrug of the isoxazoline) in the composition may vary widely depending on, for example, the mode of administration. In general, the concentration is from about 1 to about 70% (by weight). In some such embodiments, for example, the concentration is from about 1 to about 50% (by weight), or from about 10 to about 50% (by weight). In other embodiments, the concentration is from about 35 to about 65% (by weight), from about 40 to about 60% (by weight), from about 45 to about 55% (by weight), or about 50% (by weight).
  • the methods of this invention are combination therapies wherein the isoxazoline is administered in combination with one or more other active ingredients.
  • the other active ingredient(s) are one or more compounds that are not isoxazolines.
  • the other active ingredient(s) may target the same and/or different pathogens and conditions.
  • Anthelmintics are administered in combination with the isoxazoline.
  • Anthelmintics include, for example, avermectins (e.g ., ivermectin, moxidectin, and milbemycin).
  • the isoxazoline is administered in combination with (and, in some instances, in the same composition with) one or more macrocyclic lactone endectocidal parasiticides. These parasiticides tend to be useful against, for example, a broad spectrum of endoparasites and ectoparasites in mammals.
  • Ivermectin is a semi-synthetic derivative of avermectin, and is generally produced as a mixture of at least 80% 22,23-dihydroavermectin B1 a and less than 20% 22,23-dihydroavermectin B1 b .
  • Ivermectin is disclosed in US Patent 4,199,569 . Ivermectin has been used as an antiparasitic agent to treat various parasitic diseases since the mid-1980's.
  • macrocyclic lactone parasiticides include, for example:
  • the isoxazoline of Formula (11-1) may be administered before, simultaneously, and/or after the other active ingredient(s).
  • the isoxazoline may be administered in the same composition as the other active ingredient(s) and/or in a separate compositions from the other active ingredient(s).
  • the isoxazoline and other active ingredient(s) may be administered via the same and/or different routes of administration.
  • the weight ratio of the active ingredients may vary widely. Factors influencing this ratio include, for example, the particular isoxazoline; the identity of the other active ingredient(s) be administered in the combination therapy; the mode(s) of administration of the isoxazoline and other active ingredient(s); the target condition and pathogen; the type ( e.g., species and breed), age, size, sex, diet, activity, and condition of the intended recipient; and pharmacological considerations, such as the activity, efficacy, pharmacokinetic, and toxicology profiles of the isoxazoline and other active ingredient(s).
  • the weight radio of the isoxazoline to the other active ingredient(s) is from about 1:3000 to about 3000:1. In some such instances, the weight ratio is from about 1:300 to about 300:1. In other such instances, the weight ratio is from about 1:30 and about 30:1.
  • the isoxazoline may be administered with one or more other compounds that beneficially affects (e.g., enhances or prolongs) the activity (or other characteristic, such as safety) of the isoxazoline.
  • the isoxazoline may be administered with one or more synergists, such as, for example, piperonyl butoxide (PBO) and triphenyl phosphate (TPP).
  • PBO piperonyl butoxide
  • TPP triphenyl phosphate
  • synergists include, for example, N-(2-ethylhexyl)-8,9,10-trinorborn-5-ene-2,3-dicarboxamide (also known as “ENT 8184" or “MGK 264”) and Verbutin (also known as “MB-599”).
  • ENT 8184 or “MGK 264”
  • Verbutin also known as “MB-599”
  • a discussion relating to insecticidal synergists may be found in, for example, The Pesticide Manual, 13th Edition, cited above.
  • Example 1 Efficacy of Compounds 10-1 and 11-1 against cat fleas (Ctenocephalides felis).
  • the objective of these studies was to assess the efficacy of Compound 11-1 against various parasites.
  • the parasites were: Arthropoda Species Family Common name Insecta Ctenocephalides felis Pulicidae Cat flea Insecta Cimex lectularius Cimicidae Bed bug Acari Ornithodoros moubata Argasidae Chicken tick Acari Rhipicephalus sanguineus Ixodidae Brown dog tick Acari Myocoptes musculinus Myocoptidae Rodent fur mite
  • mice were divided into groups of three, and treated topically with 100 ppm body weight, orally with 10 mg/kg bodyweight, or subcutaneously with 10 mg/kg bodyweight of Compound 11-1, fipronil (positive control), or nothing (negative control). These mice were sedated and infested with adult fleas ( C . felis ) 1, 3, 6, and 24 hr after treatment. Fleas were recovered from the mice after approximately 30 minutes of feeding. The assessment of flea inhibition (% of dead and damaged fleas) was conducted 1 and 24 hr after each infestation. The results are shown in Table 1.
  • mice used in the study had a present mite infestation with M. musculinus consisting of all stages of the parasite with at least a medium (“++") infestation rate.
  • the mice were divided into groups of three, and treated topically with 100 ppm body weight, orally with 10 mg/kg body weight, or subcutaneously with 10 mg/kg body weight of Compound 11-1, fipronil (positive control), or nothing (negative control). This treatment was then repeated 7 days later.
  • Guinea pigs were treated orally, subcutaneously, or intraperitoneally with 10 mg/kg bodyweight of Compound 11-1 or fipronil (positive control).
  • the Guinea pigs were locally co-infested with juvenile soft ticks ( O . moubata ) and bed bugs ( C . lectularius ) once before the treatment, and at different time points after treatment between days 2 and 50.
  • Ten engorged ticks/bed bugs were collected to assess the percentage of killed individuals per species 24 hr after each infestation.
  • Guinea pigs were divided into groups of three. Each group was subjected to one of the following treatments with either Compound 11-1, fipronil (positive control), or neither (negative control):
  • Efficacy on engorged nymphs % ⁇ eN control group ⁇ ⁇ eN treatment group ⁇ eN control group ⁇ 100
  • collected ticks were assessed for molting into the next stage.
  • mice Ctenocephalides felis
  • mice were randomly assigned to a treatment group or a negative control (untreated) group. Each group consisted of three mice. The mice in the treatment groups were orally administered 20 mg/kg bodyweight of various isoxazolines dissolved in 7% DMF-premix and 93% purified water (aqua ad injectabilia). The application volume of these treatments was 0.01 mL/g bodyweight.
  • Each mouse was sedated and generally infested (whole body) with 30 vital, adult fleas ( C. felis). To achieve this, the sedated mice were placed into an infestation-jar, and the fleas were placed directly onto the fur. After approximately 30 minutes of feeding, fleas were recovered from the mice.
  • Example 4 Efficacy of various isoxazolines against brown dog ticks (Rhipicephalus sanguineus ) on Guinea pigs.
  • Guinea pigs were randomly assigned to a treatment group or a negative control (untreated) group. Each group consisted of three Guinea pigs. On Day Zero, each Guinea pig was infested with 100 vital nymphs of R. sanguineus. On Day 1, the Guinea pigs in the treatment groups were orally administered 10 mg/kg bodyweight of various isoxazolines dissolved in 7% DMF-premix and 93% purified water (aqua ad injectabilia).
  • Efficacy on engorged nymphs % ⁇ eN control group ⁇ ⁇ eN treatment group ⁇ eN control group ⁇ 100
  • Example 5 Efficacy of Compound 11-1 against cat fleas ( C . felis ) and brown dog ticks ( R. sanguineus ) on dogs.
  • the parasite burden of each beagle was assessed on Day 2 (approximately 48 hr after the treatment) by removing and counting the fleas and ticks.
  • Fleas and ticks were classified according to vitality (fleas: dead or alive; ticks: dead or alive, and engorged or not engorged).
  • the efficacy was calculated from the mean number of vital fleas and ticks in the treated group (Mt) relative to the mean number of vital fleas and ticks in the untreated control group (Mc) using following formula:
  • Flea / tick efficacy % Mc ⁇ Mt Mc ⁇ 100
  • Compound 11-1 exhibited a flea and tick efficacy of 100% after oral and topical treatment. No side effects were observed during this study.
  • Example 6 Further efficacy study of Compound 11-1 against cat fleas ( C . felis ) and brown dog ticks ( R. sanguineus ) on dogs.
  • Beagles were randomly assigned to 5 treatment groups of 4 animals each, and one untreated control group of 3 animals. The dogs in the treatment groups were treated on Day Zero as shown in Table 7: Table 7 Treatment Groups for Efficacy Study of Compound 11-1 against Cat Fleas ( C . felis ) and Brown Dog Ticks ( R. sanguineus ) on Beagles Group Treatment A 1 mg / kg body weight Compound 11-1 in the form of a tablet for oral administration.
  • composition was 13.33% Compound 11-1; 3.29% lactose monohydrate (Granulac 200); 0.01% of sodium lauryl sulfate; 0.90% Povidone 25; 0.15% water; 40.98% lactose monohydrate (Flowlac 100); 33.33% corn starch; 3.00% silica, colloidal anhydrous; 4.00% sodium starch glycolate; and 1.00% magnesium stearate.
  • B 1 mg / kg body weight Compound 11-1 in the form of an injectable solution for subcutaneous administration.
  • One ml of the composition contained 20 mg of Compound 11-1; 0.4 ml of dimethyl sulfoxide;0.24 ml of propylene glycol; and sufficient ethyl lactate to bring the total volume to 1 ml.
  • C 1 mg / kg body weight Compound 11-1 in the form of a topical solution for spot-on administration (the solution included an absorption enhancer).
  • One ml of the composition contained 20 mg of Compound 11-1; 0.35 ml of dimethyl sulfoxide; and sufficient dipropylene glycol monomethyl ether to bring the total volume to 1 ml.
  • D 1 mg / kg body weight Compound 11-1 in the form of a topical solution for spot-on administration the solution included an absorption enhancer and spreading agent).
  • One ml of the composition contained 20 mg of Compound 11-1; 0.35 ml of dimethyl sulfoxide; 0.1 ml of isopropyl myritate; and sufficient dipropylene glycol monomethyl ether to bring the total volume to 1 ml.
  • Group Treatment E 1 mg / kg body weight Compound 11-1 in the form of a topical solution for spot-on administration.
  • One ml of the composition contained 20 mg of Compound 11-1; and sufficient ethyl lactate to bring the total volume to 1 ml.
  • the dogs were infested with approximately 80 fleas ( C . felis ) and 60 ticks ( R. sanguineus ) on Days -2, 7, 14, 21, 28, 35, 42, and 49. Fleas and ticks were counted on Day 2 (approximately 48 h after treatment), as well as Days 9, 16, 23, 30, 37, 44, and 51 (approximately 48 hr after each post-treatment re-infestation) to evaluate the insecticidal and acaricidal activity in the treated groups. In Group B, an additional flea and tick infestation was conducted on Day 56, with a respective flea and tick count on Day 58.
  • Table 9 shows the observed flea efficacies: Table 9 Efficacies of Various Treatments with Compound 11-1 against Cat Fleas ( C. felis ) on Beagles Group Day 2 Day 9 Day 16 Day 23 Day 30 Day 37 Day 44 Day 51 Day 58 A 100 100 100 100 100 99.6 100 100 B 100 100 100 100 99.6 100 100 100 99.7 C 100 100 100 100 100 100 100 100 100 100 D 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 F 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
  • the observed mean plasma concentration of Compound 11-1 over the duration of the study is shown in Figure 1 .
  • the "PO" data refers to Group A
  • the "SC” data refers to Group B
  • the "TOP W/ ENH” data refers to Group C
  • the “TOP W/ ENH & SPREAD” data refers to Group D
  • the “TOP W/ ETHYL LACTATE” data refers to Group E.
  • the data for Group F was not included in Figure 1 , given that there was no Compound 11-1 administered to that group.
  • pharmaceutically acceptable is used adjectivally to mean that the modified noun is appropriate for use in a pharmaceutical product.
  • pharmaceutically acceptable when it is used, for example, to describe a salt, excipient, or solvate, it characterizes the salt, excipient, or solvate as being compatible with the other ingredients of the composition, and not deleterious to the intended recipient animal to the extent that the deleterious effect(s) outweighs the benefit(s) of the salt, excipient, or solvate.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Claims (12)

  1. Isoxazoline de Formule (11-1)
    Figure imgb0058
     pour une utilisation dans la lutte contre des infestations parasitaires d'un animal, une quantité de 0,01 à 200 mg/kg de poids corporel de l'isoxazoline ou d'un sel de l'isoxazoline, ou d'un solvate de l'isoxazoline ou du sel, qui est efficace pour la lutte contre une infestation ectoparasitaire, étant administrée en combinaison avec un ou plusieurs parasiticides endectocides de type lactone macrocyclique choisis parmi l'ivermectine, l'abamectine, la doramectine, la moxidectine, la sélamectine, la milbémycine, l'émamectine et l'eprinomectine, à raison d'une fréquence bimensuelle, trimestrielle, semestrielle, ou plus longue et le rapport en poids du composé de type isoxazoline et des parasiticides endectocides de type lactone macrocyclique étant de 1:3000 à 3000:1.
  2. Isoxazoline pour une utilisation selon la revendication 1, le parasiticide endectocide de type lactone macrocyclique étant l'ivermectine.
  3. Isoxazoline pour une utilisation selon la revendication 1, le parasiticide endectocide de type lactone macrocyclique étant l'abamectine.
  4. Isoxazoline pour une utilisation selon la revendication 1, le parasiticide endectocide de type lactone macrocyclique étant la doramectine.
  5. Isoxazoline pour une utilisation selon la revendication 1, le parasiticide endectocide de type lactone macrocyclique étant la moxidectine.
  6. Isoxazoline pour une utilisation selon la revendication 1, le parasiticide endectocide de type lactone macrocyclique étant la sélamectine.
  7. Isoxazoline pour une utilisation selon la revendication 1, le parasiticide endectocide de type lactone macrocyclique étant la milbémycine.
  8. Isoxazoline pour une utilisation selon la revendication 1, le parasiticide endectocide de type lactone macrocyclique étant l'émamectine.
  9. Isoxazoline pour une utilisation selon la revendication 1, le parasiticide endectocide de type lactone macrocyclique étant l'eprinomectine.
  10. Isoxazoline pour une utilisation selon l'une quelconque des revendications 1 à 9, l'animal étant un chat ou un chien.
  11. Isoxazoline pour une utilisation selon la revendication 10, l'animal étant un chat.
  12. Isoxazoline pour une utilisation selon la revendication 10, l'animal étant un chien.
EP18205103.7A 2007-08-17 2008-08-15 Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires pour les félins Active EP3473101B1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US95644807P 2007-08-17 2007-08-17
EP07016152 2007-08-17
EP07150309 2007-12-21
US8044408P 2008-07-14 2008-07-14
EP12188400.1A EP2545777B2 (fr) 2007-08-17 2008-08-15 Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires
EP08803041.6A EP2190289B1 (fr) 2007-08-17 2008-08-15 Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires
PCT/EP2008/060732 WO2009024541A2 (fr) 2007-08-17 2008-08-15 Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
EP08803041.6A Division EP2190289B1 (fr) 2007-08-17 2008-08-15 Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires
EP12188400.1A Division-Into EP2545777B2 (fr) 2007-08-17 2008-08-15 Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires
EP12188400.1A Division EP2545777B2 (fr) 2007-08-17 2008-08-15 Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires

Publications (2)

Publication Number Publication Date
EP3473101A1 EP3473101A1 (fr) 2019-04-24
EP3473101B1 true EP3473101B1 (fr) 2021-05-12

Family

ID=40152741

Family Applications (3)

Application Number Title Priority Date Filing Date
EP18205103.7A Active EP3473101B1 (fr) 2007-08-17 2008-08-15 Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires pour les félins
EP08803041.6A Active EP2190289B1 (fr) 2007-08-17 2008-08-15 Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires
EP12188400.1A Active EP2545777B2 (fr) 2007-08-17 2008-08-15 Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP08803041.6A Active EP2190289B1 (fr) 2007-08-17 2008-08-15 Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires
EP12188400.1A Active EP2545777B2 (fr) 2007-08-17 2008-08-15 Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires

Country Status (20)

Country Link
US (5) US20110059988A1 (fr)
EP (3) EP3473101B1 (fr)
JP (4) JP5411135B2 (fr)
KR (3) KR101725320B1 (fr)
CN (2) CN101778566A (fr)
AU (2) AU2008290581C1 (fr)
BR (2) BR122020005235B1 (fr)
CA (1) CA2694919C (fr)
DK (2) DK2190289T3 (fr)
ES (2) ES2785104T5 (fr)
HK (1) HK1143037A1 (fr)
MX (2) MX351346B (fr)
NO (1) NO2016018I1 (fr)
NZ (2) NZ599797A (fr)
PL (2) PL2190289T3 (fr)
PT (1) PT2190289E (fr)
RU (3) RU2481837C2 (fr)
TW (1) TWI556741B (fr)
WO (1) WO2009024541A2 (fr)
ZA (1) ZA201203080B (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101197482B1 (ko) 2004-03-05 2012-11-09 닛산 가가쿠 고교 가부시키 가이샤 이속사졸린 치환 벤즈아미드 화합물 및 유해생물 방제제
TW200803740A (en) * 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
EP2151437A4 (fr) * 2007-03-07 2012-05-02 Nissan Chemical Ind Ltd Composé de benzamide substitué par isoxazoline et agent de contrôle des nuisibles
EP2155701B1 (fr) * 2007-06-13 2013-12-11 E. I. Du Pont de Nemours and Company Insecticides à l'isoxazoline
PL2957284T3 (pl) 2007-06-27 2018-08-31 E. I. Du Pont De Nemours And Company Sposób zwalczania szkodników zwierzęcych
TWI649303B (zh) 2007-08-17 2019-02-01 杜邦股份有限公司 製備４-乙醯基-ｎ-〔２-側氧基-２-〔（２，２，２-三氟乙基）胺基〕乙基〕-１-萘甲醯胺之化合物及方法
TWI556741B (zh) * 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
TWI455919B (zh) 2008-04-09 2014-10-11 Du Pont 製備３－三氟甲基查耳酮（ｃｈａｌｃｏｎｅ）之方法
ES2582575T3 (es) 2008-07-09 2016-09-13 Nissan Chemical Industries, Ltd. Procedimiento para la producción de compuesto de amida del ácido benzoico sustituido con isoxazolina
ES2635120T5 (es) 2008-07-09 2024-06-03 Basf Se Mezclas activas de pesticidas que comprenden compuestos I de isoxazolina
EP2331536B1 (fr) 2008-08-22 2013-08-21 Syngenta Participations AG Composés insecticides
US8822502B2 (en) 2008-08-22 2014-09-02 Syngenta Crop Protection Llc Insecticidal compounds
AU2009289711A1 (en) 2008-09-04 2010-03-11 Syngenta Limited Insecticidal compounds
AU2009313920B2 (en) 2008-11-14 2014-10-23 Boehringer Ingelheim Animal Health USA Inc. Enantiomerically enriched aryloazol- 2 -yl cyanoethylamino paraciticidal compounds
MX2011005184A (es) 2008-11-19 2011-07-28 Merial Ltd Composiciones que comprenden un aril pirazol y/o una formamidina, metodos y usos de las mismas.
BRPI0922709B8 (pt) 2008-12-04 2017-03-14 Merial Ltd derivados diméricos de avermectina e milbemicina
ES2524970T3 (es) 2009-04-30 2014-12-16 Basf Se Procedimiento de preparación de compuestos de isoxazolina sustituidos y sus precursores
TWI487486B (zh) 2009-12-01 2015-06-11 Syngenta Participations Ag 以異唑啉衍生物為主之殺蟲化合物
BR112012014921B1 (pt) 2009-12-17 2020-11-03 Merial, Inc. compostos dihidroazol parasiticidas e composições compreendendo os mesmos
UA108641C2 (uk) 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
HUE028501T2 (en) 2010-05-27 2016-12-28 Du Pont 4- [5- [3-Chloro-5- (trifluoromethyl) phenyl] -4,5-dihydro-5- (trifluoromethyl) -3-isoxazolyl] -N- [2-oxo-2 - [(2.2, 2-Trifluoroethyl) amino] ethyl] -1-naphthalenecarboxamide crystalline form
TW201211057A (en) * 2010-06-11 2012-03-16 Syngenta Participations Ag Process for the preparation of dihydropyrrole derivatives
BR112012032496A2 (pt) 2010-06-23 2015-09-15 Basf Se processos para produzir um composto de carbonila da fórmula i e de imina da fórmula iii, compostos de imina da fórmula (iii), composições agrícolas e veterinária, uso de um composto de imina da fórmula iii e material de propagação de planta
WO2012007426A1 (fr) 2010-07-13 2012-01-19 Basf Se Composés d'isoxazoline benzamide à substitution azoline pour lutter contre les organismes nuisibles
WO2012059441A2 (fr) 2010-11-03 2012-05-10 Basf Se Procédé de préparation de composés isoxazolines substituées et leurs précurseurs 4-chloro-, 4-bromo- ou 4-iodobenzaldéhyde oximes
JP2014015397A (ja) * 2010-11-04 2014-01-30 Nippon Soda Co Ltd 動物用外部寄生虫防除剤
DE102010063691A1 (de) 2010-12-21 2012-06-21 Bayer Animal Health Gmbh Ektoparasitizide Wirkstoffkombinationen
KR102193090B1 (ko) * 2010-12-27 2020-12-21 인터벳 인터내셔널 비.브이. 국소 적용 이속사졸린 제제
JP2014506249A (ja) 2010-12-27 2014-03-13 インターベツト・インターナシヨナル・ベー・ベー グリコフロールを含む経表面局所イソオキサゾリン製剤
WO2012089622A2 (fr) 2010-12-27 2012-07-05 Intervet International B.V. Préparation à base d'isoxazoline pour application topique
WO2012155352A1 (fr) 2011-05-19 2012-11-22 Eli Lilly And Company Composés de dihydroisoxazole, utilisations antiparasitaires et préparations associées
JP6041359B2 (ja) 2011-06-27 2016-12-07 メリアル インコーポレイテッド アミドピリジルエーテル化合物及び組成物並びに寄生虫に対するそれらの使用
CA2848317C (fr) 2011-09-12 2021-01-19 Merial Limited Compositions antiparasitaires comprenant un agent actif d'isoxazoline, procedes et utilisations associes.
WO2013074892A1 (fr) 2011-11-17 2013-05-23 Merial Limited Compositions comprenant un aryl pyrazole et un imidazole substitué, procédés et utilisations de celles-ci
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
BR112014012942A2 (pt) * 2011-11-29 2017-06-13 Novartis Ag uso de derivados de aril para controle de ectoparasitas
CA2857958C (fr) 2011-12-02 2020-08-25 Merial Limited Formulations de moxidectine injectable a action prolongee et cristal de moxidectine
AU2013217633B2 (en) 2012-02-06 2017-01-12 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
JO3626B1 (ar) 2012-02-23 2020-08-27 Merial Inc تركيبات موضعية تحتوي على فيبرونيل و بيرميثرين و طرق استخدامها
AU2013245011B2 (en) 2012-04-04 2017-11-23 Intervet International B.V. Solid oral pharmaceutical compositions for isoxazoline compounds
EP3763706A1 (fr) 2012-04-20 2021-01-13 Boehringer Ingelheim Animal Health USA Inc. Compositions parasiticides comprenant des dérivés de benzimidazole, procédés et utilisations associés
AU2013245478A1 (en) * 2012-11-01 2014-05-15 Sumitomo Chemical Company, Limited Method for administering agent for controlling ectoparasite to dog
JP6506694B2 (ja) 2012-11-20 2019-04-24 メリアル インコーポレイテッド 駆虫性化合物及び組成物並びにこれらの使用方法
US9532946B2 (en) * 2012-11-20 2017-01-03 Intervet Inc. Manufacturing of semi-plastic pharmaceutical dosage units
SI2953942T1 (en) 2013-02-06 2018-03-30 Bayer Cropscience Ag Halogen-substituted pyrazole derivatives such as pesticides
BR112015023435B1 (pt) 2013-03-15 2022-05-03 Douglas Robert Cleverly Formulação mastigável estável sob armazenagem e método de fabricação de uma formulação mastigável, palatável e estável sob armazenagem
US11446241B2 (en) 2013-07-29 2022-09-20 Attillaps Holdings Inc. Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
US10709135B2 (en) 2013-07-29 2020-07-14 Attillaps Holdings Organophosphates for treating afflictions of the skin
US9371293B2 (en) * 2013-10-25 2016-06-21 Sumitomo Chemical Company, Limited Isoxazoline compound composition
EP3063144B1 (fr) 2013-11-01 2021-09-08 Boehringer Ingelheim Animal Health USA Inc. Composés d'isoxazoline antiparasitaires et pesticides
PL3079474T3 (pl) 2013-12-10 2019-10-31 Intervet Int Bv Zastosowanie związków izoksazoliny jako środków przeciwpasożytniczych
EP4306168A3 (fr) * 2013-12-20 2024-03-13 Intervet International B.V. Compositions d'isoxazoline et leur utilisation dans la prévention ou le traitement d'infestations de parasites chez des animaux
MX2016008119A (es) 2013-12-20 2016-09-16 Intervet Int Bv Uso de derivados de isoxazolina para el tratamiento o prevencion de infestaciones por artropodos en aves de corral.
ES2683693T3 (es) 2014-01-03 2018-09-27 Bayer Animal Health Gmbh Nuevas pirazolil-heteroarilamidas como agentes plaguicidas
EP3131398B1 (fr) 2014-04-17 2019-10-23 Boehringer Ingelheim Animal Health USA Inc. Utilisation de composés de malononitrile pour protéger des animaux contre les parasites
US10045979B2 (en) 2014-05-19 2018-08-14 Merial Inc. Anthelmintic compounds
PT3157534T (pt) 2014-06-19 2022-08-04 Attillaps Holdings Inibidores de acetilcolinestérase para o tratamento de condições da dermatológicas
EA030459B1 (ru) 2014-06-19 2018-08-31 Мериал, Инк. Паразитицидные композиции, содержащие индольные производные, способы их получения и их применение
WO2016008830A1 (fr) 2014-07-15 2016-01-21 Bayer Cropscience Aktiengesellschaft Aryl-triazolyl-pyridines en tant que pesticides
NZ731446A (en) 2014-10-31 2018-09-28 Boehringer Ingelheim Animal Health Usa Inc Parasiticidal composition comprising fipronil
WO2016102437A1 (fr) 2014-12-22 2016-06-30 Intervet International B.V. Utilisation de composés d'isoxazoline pour le traitement de la gale démodectique
UY36570A (es) 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
CN108055825B (zh) 2015-04-08 2021-03-30 勃林格殷格翰动物保健美国公司 包含异噁唑啉活性剂的延长释放可注射制剂、其方法和用途
BR112017024773A2 (pt) 2015-05-20 2018-11-06 Merial, Inc. compostos depsipeptídeos anti-helmínticos
WO2016207234A1 (fr) * 2015-06-23 2016-12-29 Intervet International B.V. Solution d'isoxazoline contenant de la vitamine e pour une utilisation avec de l'eau potable désinfectée
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
EA201892245A1 (ru) 2016-04-06 2019-07-31 Мериал, Инк. Способ получения энантиомерно-обогащенных изоксазолиновых соединений - кристаллический толуольный сольват(s)-афоксоланера
WO2018039508A1 (fr) 2016-08-25 2018-03-01 Merial, Inc. Procédé de réduction d'effets indésirables dans des traitements antiparasitaires
AU2017344097A1 (en) 2016-10-14 2019-05-02 Boehringer Ingelheim Animal Health USA Inc. Pesticidal and parasiticidal vinyl isoxazoline compounds
WO2018093920A1 (fr) 2016-11-16 2018-05-24 Merial, Inc. Composés depsipeptidiques anthelminthiques
CN107535503A (zh) * 2017-07-21 2018-01-05 陕西康禾立丰生物科技药业有限公司 一种含有氟噁唑酰胺和新烟碱类的杀虫组合物
US11589586B2 (en) 2017-08-14 2023-02-28 Boehringer Ingelheim Animal Health USA Inc. Pesticidal and parasiticidal pyrazole-isoxazoline compounds
CN107593723A (zh) * 2017-09-29 2018-01-19 北京科发伟业农药技术中心 一种含fluxametamide的组合物
UA127456C2 (uk) 2017-11-07 2023-08-30 Інтервет Інтернешнл Б.В. Ін'єкційна ізоксазолінова фармацевтична композиція та її застосування
EP3707129A1 (fr) 2017-11-07 2020-09-16 Intervet International B.V. Procédé de préparation de particules d'isoxazoline de grandes tailles
AU2018385363B2 (en) 2017-12-12 2024-06-13 Intervet International B.V. Implantable isoxazoline pharmaceutical compositions and uses thereof
IL275339B2 (en) 2017-12-15 2024-03-01 Tarsus Pharmaceuticals Inc Parasitic formulations containing isoxazoline and methods for treating blepharitis
AR113997A1 (es) 2017-12-21 2020-07-08 Intervet Int Bv Composiciones antiparasitarias para unción dorsal continua
WO2019157241A1 (fr) 2018-02-08 2019-08-15 Boehringer Ingelheim Animal Health USA Inc. Compositions parasiticides comprenant de l'éprinomectine et du praziquantel, procédés et utilisations associés
US20220048903A1 (en) 2018-07-09 2022-02-17 Boehringer Ingelheim Animal Health USA Inc. Anthelminthic Heterocyclic Compounds
EP3883648A1 (fr) 2018-11-20 2021-09-29 Boehringer Ingelheim Animal Health USA Inc. Composé indazolylcyanoéthylamino, compositions associées, procédé de fabrication et procédés d'utilisation de celui-ci
NZ776819A (en) 2019-01-16 2023-04-28 Boehringer Ingelheim Animal Health Usa Inc Topical compositions comprising a neonicotinoid and a macrocyclic lactone, methods and uses thereof
CA3129329A1 (fr) 2019-03-01 2020-09-10 Boehringer Ingelheim Animal Health USA Inc. Compositions injectables de clorsulon, procedes et utilisations de celles-ci
WO2020191091A1 (fr) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Composés d'aza-benzothiophène et d'aza-benzofurane anthelminthiques
EP3946325A4 (fr) * 2019-04-04 2022-12-21 Tarsus Pharmaceuticals, Inc. Parasiticides systémiques à base d'isoxazoline pour le traitement ou la prophylaxie d'une maladie virale et à vecteur
EP3962448A1 (fr) 2019-05-03 2022-03-09 Intervet International B.V. Compositions pharmaceutiques injectables et leurs utilisations
WO2021000865A1 (fr) * 2019-07-01 2021-01-07 沈阳化工大学 Composé d'isoxazoline, son procédé de préparation et son application
MX2022000843A (es) 2019-07-22 2022-02-10 Intervet Int Bv Forma de dosificacion blanda masticable de uso veterinario.
WO2021122521A1 (fr) 2019-12-16 2021-06-24 Intervet International B.V. Composition pour lutter contre les poux chez la volaille
AU2020404003A1 (en) 2019-12-16 2022-05-26 Intervet International B.V. Parasite control in ruminants
EP4075981A1 (fr) * 2019-12-16 2022-10-26 Intervet International B.V. Composition pour lutter contre les poux
PT4153133T (pt) 2020-05-20 2024-01-12 Intervet Int Bv Composições farmacêuticas injetáveis e utilizações das mesmas
WO2021242481A1 (fr) 2020-05-28 2021-12-02 Boehringer Ingelheim Animal Health USA Inc. Dispositif de capsule intraruminale à libération bimodale et ses méthodes d'utilisation
BR112022024156A2 (pt) 2020-05-29 2023-02-14 Boehringer Ingelheim Animal Health Usa Inc Compostos heterocílicos antelmínticos
CN111657292A (zh) * 2020-06-03 2020-09-15 浙江中山化工集团股份有限公司 一种含有氟噁唑酰胺和高效氯氰菊酯的杀虫组合物
CN111909143B (zh) * 2020-07-30 2021-10-29 山东省联合农药工业有限公司 一种异噁唑啉取代的苯甲酰胺类衍生物及其制备方法与用途
AU2021401834A1 (en) 2020-12-18 2023-07-06 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
EP4262789A1 (fr) 2020-12-21 2023-10-25 Boehringer Ingelheim Vetmedica GmbH Collier parasiticide comprenant des composés d'isoxazoline
WO2022162016A1 (fr) 2021-01-27 2022-08-04 Intervet International B.V. Composés de cyclopropylamide contre des parasites chez les poissons
US20240116854A1 (en) 2021-01-27 2024-04-11 Intervet Inc. Cyclopropylamide compounds against parasites in fish
AU2022232510A1 (en) * 2021-03-11 2023-09-21 In The Bowl Animal Health, Inc. Oral canine feed and methods for controlling flea infestations in a canine
JP2024511956A (ja) * 2021-03-11 2024-03-18 イン ザ ボウル アニマル ヘルス，インコーポレーテッド 経口のイヌ科動物の飼料およびイヌ科動物におけるダニの侵入を制御する方法
WO2022226660A1 (fr) * 2021-04-30 2022-11-03 Ohalloran John Utilisation d'isoxazoline pour protéger des poissons contre des parasites
BR112023027372A2 (pt) 2021-06-25 2024-03-12 Intervet Int Bv Composições veterinárias palatáveis
CN113563322B (zh) * 2021-07-26 2023-07-07 海利尔药业集团股份有限公司 一种取代的苯甲酰胺类异噁唑啉衍生物或其作为农药可接受的盐、组合物及其用途
KR102660238B1 (ko) * 2021-12-20 2024-04-25 주식회사경농 다이하이드로아이소옥사졸 유도체 화합물 및 이를 포함하는 살충제 조성물
US20230312207A1 (en) 2022-02-17 2023-10-05 Boehringer Ingelheim Vetmedica Gmbh Method and system for providing a fluid product mailer
CN117126116A (zh) * 2022-05-20 2023-11-28 天津瑞普生物技术股份有限公司 一种异噁唑啉类化合物的衍生物及其应用
CN117122571A (zh) * 2022-05-20 2023-11-28 天津瑞普生物技术股份有限公司 一种抗寄生虫感染的口服药物制剂及其制备方法和应用
KR20240002746A (ko) * 2022-06-30 2024-01-08 주식회사경농 이속사졸린 유도체 화합물 및 이를 포함하는 살충제 조성물
CN115785017B (zh) * 2022-12-06 2023-12-08 海利尔药业集团股份有限公司 一种取代的苯酰胺异噁唑啉衍生物或其作为农药可接受的盐、组合物及其用途

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002042A1 (fr) 1996-07-11 1998-01-22 Merial Procedes d'elimination des parasites et notamment des ectoparasites de vertebres, notamment de mammiferes et compositions pour la mise en oeuvre de ce procede
WO1998011780A1 (fr) 1996-09-19 1998-03-26 Merial Nouvelle association parasiticide
EP1066854A2 (fr) 1999-07-08 2001-01-10 Pfizer Inc. Compositions anthelminthiques contenant un dérivé d'avermectin ou de milbemycin et un composé bis-aryle
EP1671941A1 (fr) 2003-09-30 2006-06-21 Nissan Chemical Industries, Ltd. Compose benzanilide substitue et agent de lutte contre les parasites
EP1672941A1 (fr) 2004-12-15 2006-06-21 Matsushita Electric Industrial Co., Ltd. Support du traffic à débit binaire garanti pour les transmissions de la liaison montante
EP1731512A1 (fr) 2004-03-05 2006-12-13 Nissan Chemical Industries, Ltd. Compose benzamide substitue par de l'isoxazoline et agent de contrôle d'organisme nocif
WO2007018659A1 (fr) 2005-05-16 2007-02-15 Merial Limited Formulations de traitement cutane localise contre les parasites
WO2007067470A2 (fr) 2005-12-06 2007-06-14 Wyeth Compositions non aqueuses de benzimidazole
WO2007070606A2 (fr) 2005-12-14 2007-06-21 E. I. Du Pont De Nemours And Company Isoxazolines destinees au controle des invertebres nuisibles
WO2007075459A2 (fr) 2005-12-16 2007-07-05 E. I. Du Pont De Nemours And Company 5-arylisoxazolines pour lutter contre des parasites invertebres
WO2007079162A1 (fr) 2005-12-30 2007-07-12 E. I. Du Pont De Nemours And Company Isoxazolines servant à lutter contre des animaux nuisibles invertébrés
WO2008055881A1 (fr) 2006-11-10 2008-05-15 Basf Se Modification cristalline de fipronil
WO2009003075A1 (fr) 2007-06-27 2008-12-31 E.I. Du Pont De Nemours And Company Procédé de lutte contre les parasites des animaux
US8044409B2 (en) 2008-08-11 2011-10-25 Taiwan Semiconductor Manufacturing Company, Ltd. III-nitride based semiconductor structure with multiple conductive tunneling layer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984564A (en) 1972-06-08 1976-10-05 Sankyo Company Limited Antibiotic substances B-41, their production and their use as insecticides and acaricides
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
ES8800986A1 (es) 1985-07-27 1987-12-01 Pfizer Un procedimiento para la produccion de un nuevo derivado de avermectina
US4916154A (en) 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
IL98599A (en) 1990-06-28 1995-06-29 Merck & Co Inc Stable salts of "4-deoxy-" 4-epi-methylamino abramectin and insecticides containing them
WO1992000964A1 (fr) 1990-07-05 1992-01-23 Nippon Soda Co., Ltd. Derive d'amine
GB9205007D0 (en) * 1992-03-07 1992-04-22 Pfizer Ltd Antiparasitic agents
US5399717A (en) 1993-09-29 1995-03-21 Merck & Co., Inc. Glycosidation route to 4"-epi-methylamino-4"-deoxyavermectin B1
US5399582A (en) 1993-11-01 1995-03-21 Merck & Co., Inc. Antiparasitic agents
WO1996029073A1 (fr) 1995-03-20 1996-09-26 Merck & Co., Inc. Derives de l'acide nodulisporique
US5962499A (en) 1995-03-20 1999-10-05 Merck & Co., Inc. Nodulisporic acid derivatives
US5595991A (en) 1995-03-20 1997-01-21 Merck & Co., Inc. Anthelmintic use of nodulisporic acid and analogs thereof
US6221894B1 (en) 1995-03-20 2001-04-24 Merck & Co., Inc. Nodulisporic acid derivatives
US5834260A (en) 1996-08-30 1998-11-10 Merck & Co., Inc. Antiparasitic agents
FR2761232B1 (fr) 1997-03-26 2000-03-10 Rhone Merieux Procede et moyens d'eradication des puces dans les locaux habites par les petits mammiferes
RU2129430C1 (ru) * 1998-03-17 1999-04-27 Общество С Ограниченной Ответственностью "Вик - Здоровье Животных" Препарат для борьбы с экто- и эндопаразитами животных "сантомектин"
US6265384B1 (en) * 1999-01-26 2001-07-24 Dale L. Pearlman Methods and kits for removing, treating, or preventing lice with driable pediculostatic agents
RU2149007C1 (ru) * 1999-09-28 2000-05-20 Закрытое акционерное общество "Агроветсервис" Антипаразитарная, антимикробная противовоспалительная мазь пролонгированного действия
ATE402156T1 (de) * 2000-12-08 2008-08-15 Us Gov Health & Human Serv Schädlingsbekämpfungsverbindungen
GB0402677D0 (en) 2003-11-06 2004-03-10 Novartis Ag Organic compounds
AU2004312506B2 (en) 2003-12-31 2011-08-04 Schering-Plough Pty. Limited Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives
US7361689B2 (en) 2003-12-31 2008-04-22 Schering-Plough Animal Health Corporation Antibacterial 1-(4-mono- and di-halomethylsulphonylphenyl)-2-acylamino-3-fluoroproponals and preparation thereof
CN101065352A (zh) 2004-09-23 2007-10-31 先灵-普劳有限公司 使用新的三氟甲磺酰苯胺肟醚衍生物控制动物中的寄生虫
JP5112074B2 (ja) 2004-11-09 2013-01-09 ノバルティス アーゲー アミドアセトニトリル化合物のラセミ体からのアミドアセトニトリル化合物の鏡像異性体の調製方法
DE602005017419D1 (de) 2004-11-19 2009-12-10 Schering Plough Ltd Kontrolle von parasiten bei tieren mittels verwendung von parasitiziden 2-phenyl-3-(1h-pyrrol-2-yl) acrylonitril-derivaten
PE20070108A1 (es) 2005-06-09 2007-02-09 Schering Plough Ltd Control de parasitos en animales con derivados de n-[(feniloxi)fenil]-1,1,1-trifluorometansulfonamida y de n-[(fenilsulfanil)fenil]-1,1,1-trifluorometansulfonamida
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
JP4479917B2 (ja) 2005-09-02 2010-06-09 日産化学工業株式会社 イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
CA2621228C (fr) 2005-09-02 2014-05-27 Nissan Chemical Industries, Ltd. Compose de benzamide a substitution isoxazoline et agent de lutte contre les organismes nuisibles
DE102006015470A1 (de) 2006-03-31 2007-10-04 Bayer Cropscience Ag Substituierte Enaminocarbonylverbindungen
JP2008133242A (ja) 2006-11-29 2008-06-12 Nissan Chem Ind Ltd 置換フェニルリチウム化合物の製造方法
TWI556741B (zh) * 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002042A1 (fr) 1996-07-11 1998-01-22 Merial Procedes d'elimination des parasites et notamment des ectoparasites de vertebres, notamment de mammiferes et compositions pour la mise en oeuvre de ce procede
WO1998011780A1 (fr) 1996-09-19 1998-03-26 Merial Nouvelle association parasiticide
EP1066854A2 (fr) 1999-07-08 2001-01-10 Pfizer Inc. Compositions anthelminthiques contenant un dérivé d'avermectin ou de milbemycin et un composé bis-aryle
EP1671941A1 (fr) 2003-09-30 2006-06-21 Nissan Chemical Industries, Ltd. Compose benzanilide substitue et agent de lutte contre les parasites
US20070066617A1 (en) 2004-03-05 2007-03-22 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and pesticide
EP1731512A1 (fr) 2004-03-05 2006-12-13 Nissan Chemical Industries, Ltd. Compose benzamide substitue par de l'isoxazoline et agent de contrôle d'organisme nocif
EP1672941A1 (fr) 2004-12-15 2006-06-21 Matsushita Electric Industrial Co., Ltd. Support du traffic à débit binaire garanti pour les transmissions de la liaison montante
WO2007018659A1 (fr) 2005-05-16 2007-02-15 Merial Limited Formulations de traitement cutane localise contre les parasites
WO2007067470A2 (fr) 2005-12-06 2007-06-14 Wyeth Compositions non aqueuses de benzimidazole
WO2007070606A2 (fr) 2005-12-14 2007-06-21 E. I. Du Pont De Nemours And Company Isoxazolines destinees au controle des invertebres nuisibles
WO2007075459A2 (fr) 2005-12-16 2007-07-05 E. I. Du Pont De Nemours And Company 5-arylisoxazolines pour lutter contre des parasites invertebres
WO2007079162A1 (fr) 2005-12-30 2007-07-12 E. I. Du Pont De Nemours And Company Isoxazolines servant à lutter contre des animaux nuisibles invertébrés
WO2008055881A1 (fr) 2006-11-10 2008-05-15 Basf Se Modification cristalline de fipronil
WO2009003075A1 (fr) 2007-06-27 2008-12-31 E.I. Du Pont De Nemours And Company Procédé de lutte contre les parasites des animaux
US8044409B2 (en) 2008-08-11 2011-10-25 Taiwan Semiconductor Manufacturing Company, Ltd. III-nitride based semiconductor structure with multiple conductive tunneling layer

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
"Macrocyclic lactones in antiparasitic therapy", CABI, 2002, pages 432
"Veterinary Ectoparasites: Biology, Pathology and Control, Second Edition", June 2001, article R. WALL , DAVID SHEARER
ANONYMOUS: "Advantage Multi for dogs. Imidacloprid + Moxidectin", FREEDOM OF INFORMATION SUMMARY NADA 141-251, 20 December 2006 (2006-12-20), XP055896920
ANONYMOUS: "Advantage® DUO", FREEDOM OF INFORMATION SUMMARY NADA 141-208, 27 September 2002 (2002-09-27), XP055896864
ANONYMOUS: "HEARTGARD-30®", FREEDOM OF INFORMATION SUMMARY - NADA 138-412, 2 March 1987 (1987-03-02), pages 1 - 20, XP055896027, [retrieved on 20220228]
ANONYMOUS: "HEARTGARD™ for Cats", FREEDOM OF INFORMATION SUMMARY - NADA 141-078, 23 December 1996 (1996-12-23), pages 1 - 21, XP055896033, [retrieved on 20220228]
ANONYMOUS: "Interceptor®", FREEDOM OF INFORMATION SUMMARY - NADA 140-915, 9 September 1996 (1996-09-09), pages 1 - 4, XP055896029, [retrieved on 20220228]
ANONYMOUS: "Proheart for dogs", FREEDOM OF INFORMATION SUMMARY - NADA 141-051, 27 May 1997 (1997-05-27), pages 1 - 17, XP055896819, Retrieved from the Internet <URL:https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/3629>
ANONYMOUS: "REVOLUTION®", FREEDOM OF INFORMATION SUMMARY - NADA 141-152, 13 June 2000 (2000-06-13), XP055896043, [retrieved on 20220228]
ANONYMOUS: "SENTINEL* (milbemycin oxime/Iufenuron) Flavor Tabs* and CAPSTAR* (nitenpyram) Tablets", FREEDOM OF INFORMATION SUMMARY NADA 141-204, 11 June 2003 (2003-06-11), XP055896901
BURONFOSSE-ROQUE FLORENCE, FANNY BELLEBEAU-BARBIER, XAVIER PINEAU, STÉPHANE QUEFFÉLEC: "Propriétés pharmacologiques et toxicologiques des antiparasitaires externes", LE POINT VÉTÉRINAIRE, no. 374, 1 April 2017 (2017-04-01), XP055896040
FISARA ET AL.: "Efficacy of a spot-on combination of fluralaner plus moxidectin (Bravecto Plus) in cats following repeated experimental challenge with a field isolate of Ctenocephalides felis", PARASITES VECTORS, vol. 12, no. 259, 2019 *
MCCALL, J.W.: "The safety-net story about macrocyclic lactone heartworm preventives: A review, an update, and recommendations", VETERINARY PARASITOLOGY, ELSEVIER SCIENCE, AMSTERDAM., NL, vol. 133, no. 2-3, 24 October 2005 (2005-10-24), NL , pages 197 - 206, XP027655651, ISSN: 0304-4017
NADEGE CHAILLEUX, MANON PARADIS: "Efficacy of selamectin in the treatment of naturally acquired cheyletiellosis in cats", CAN. VET. J., vol. 43, 1 October 2002 (2002-10-01), pages 767 - 770, XP055762857
NADEGE CHAILLEUX, MANON PARADIS: "Efficacy of selamectin in the treatment of naturally acquired cheyletiellosis in cats", CAN. VET. J., vol. 43, no. 10, 1 October 2002 (2002-10-01), pages 767 - 770, XP055762857
OZOE, Y. ; ASAHI, M. ; OZOE, F. ; NAKAHIRA, K. ; MITA, T.: "The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 391, no. 1, 1 January 2010 (2010-01-01), Amsterdam NL , pages 744 - 749, XP026823770, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2009.11.131
OZOE, Y. ; ASAHI, M. ; OZOE, F. ; NAKAHIRA, K. ; MITA, T.: "The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 391, no. 1, 1 January 2010 (2010-01-01), Amsterdam NL , pages 744 - 749, XP026907975, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2009.11.131
VERCRUYSSE J.: "Macrocyclic lactones in antiparasitic therapy", ACADEMIA, 2002, pages 1 - 447
WALL RICHARD, SHEARER DAVID: "Veterinary Ectoparasites: Biology, Pathology and Control", BLACKWELL SCIENCE, 1 June 2001 (2001-06-01), pages 1 - 275, XP055948851

Also Published As

Publication number Publication date
PT2190289E (pt) 2013-08-22
EP2545777B1 (fr) 2020-03-11
EP2190289B1 (fr) 2013-05-01
NO2016018I1 (no) 2016-10-05
KR101725320B1 (ko) 2017-04-10
RU2481837C2 (ru) 2013-05-20
BRPI0815227B1 (pt) 2021-02-23
ES2785104T3 (es) 2020-10-05
RU2010109901A (ru) 2011-09-27
JP2010536733A (ja) 2010-12-02
US20160332975A1 (en) 2016-11-17
CN103705509A (zh) 2014-04-09
US20150111936A1 (en) 2015-04-23
NZ583045A (en) 2012-06-29
CN101778566A (zh) 2010-07-14
AU2008290581C1 (en) 2019-07-11
JP2014097982A (ja) 2014-05-29
NZ599797A (en) 2013-08-30
PL2545777T5 (pl) 2023-03-27
CA2694919C (fr) 2017-10-17
JP2016147888A (ja) 2016-08-18
ES2785104T5 (es) 2023-04-28
AU2013207639B2 (en) 2016-05-12
BR122020005235B1 (pt) 2023-11-14
RU2016133168A3 (fr) 2019-12-12
ZA201203080B (en) 2012-12-27
DK2190289T3 (da) 2013-07-29
ES2417157T3 (es) 2013-08-06
EP2190289A2 (fr) 2010-06-02
US20210061775A1 (en) 2021-03-04
RU2016133168A (ru) 2018-02-16
BRPI0815227A2 (pt) 2019-08-06
MX2010001907A (es) 2010-04-27
MX351346B (es) 2017-10-11
JP6458095B2 (ja) 2019-01-23
JP5411135B2 (ja) 2014-02-12
PL2545777T3 (pl) 2020-06-15
RU2013107094A (ru) 2014-08-27
KR20160032278A (ko) 2016-03-23
TWI556741B (zh) 2016-11-11
WO2009024541A2 (fr) 2009-02-26
JP6014006B2 (ja) 2016-10-25
RU2602308C2 (ru) 2016-11-20
EP2545777B2 (fr) 2023-01-18
KR101792547B1 (ko) 2017-11-02
CA2694919A1 (fr) 2009-02-26
EP2545777A1 (fr) 2013-01-16
US20180155301A1 (en) 2018-06-07
KR20170041281A (ko) 2017-04-14
WO2009024541A3 (fr) 2010-04-01
AU2008290581A1 (en) 2009-02-26
DK3473101T3 (da) 2021-07-12
HK1143037A1 (en) 2010-12-24
EP3473101A1 (fr) 2019-04-24
US20110059988A1 (en) 2011-03-10
KR20100057066A (ko) 2010-05-28
TW200924649A (en) 2009-06-16
PL2190289T3 (pl) 2013-09-30
AU2008290581B2 (en) 2013-07-25
RU2715051C2 (ru) 2020-02-25
JP2017222692A (ja) 2017-12-21
JP6251308B2 (ja) 2017-12-20

Similar Documents

Publication Publication Date Title
EP3473101B1 (fr) Compostions d&#39;isoxazoline et leur utilisation en tant qu&#39;antiparasitaires pour les félins
AU2022203370B2 (en) Isoxazoline compositions and their use as antiparasitics
RU2816320C2 (ru) Изоксазолиновые композиции и их применение в качестве противопаразитарных средств
ES2877329T3 (es) Composiciones de isoxazolina y su uso como antiparasitarios para felinos
AU2018203263A1 (en) Isoxazoline compositions and their use as antiparasitics
BR122020024991B1 (pt) Uso de isoxazolina

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2545777

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2190289

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191024

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200303

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20201106

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HECKEROTH, ANJA, REGINA,

Inventor name: LUTZ, JUERGEN

Inventor name: ZOLLER, HARTMUT

Inventor name: MERTENS, CHRISTINA

Inventor name: WILLIAMS, HEIKE

Inventor name: MITA, TAKESHI

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210301

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 2190289

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2545777

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008063971

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1391566

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210615

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3473101

Country of ref document: PT

Date of ref document: 20210628

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20210622

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210705

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20210512

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1391566

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210812

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2877329

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210912

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210813

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602008063971

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

REG Reference to a national code

Ref country code: FI

Ref legal event code: MDE

Opponent name: VIRBAC

Ref country code: FI

Ref legal event code: MDE

Opponent name: CEVA SANTE ANIMALE

26 Opposition filed

Opponent name: VIRBAC

Effective date: 20220211

Opponent name: CEVA SANTE ANIMALE

Effective date: 20220211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210912

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210815

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210815

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20080815

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20230628

Year of fee payment: 16

Ref country code: DK

Payment date: 20230627

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230720

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20230726

Year of fee payment: 16

Ref country code: IT

Payment date: 20230810

Year of fee payment: 16

Ref country code: GB

Payment date: 20230712

Year of fee payment: 16

Ref country code: FI

Payment date: 20230727

Year of fee payment: 16

Ref country code: ES

Payment date: 20230906

Year of fee payment: 16

Ref country code: CH

Payment date: 20230901

Year of fee payment: 16

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230808

Year of fee payment: 16

Ref country code: FR

Payment date: 20230710

Year of fee payment: 16

Ref country code: DE

Payment date: 20230711

Year of fee payment: 16

Ref country code: BE

Payment date: 20230712

Year of fee payment: 16

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO